Sofigatran is primarily used as an anticoagulant, specifically targeting thrombin inhibition. It is applied in the prevention and treatment of thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. Its mechanism of action involves direct thrombin inhibition, which helps in reducing the risk of blood clot formation. This makes it particularly useful in patients undergoing surgeries or those with conditions that predispose them to clotting. Additionally, it is being studied for its potential use in stroke prevention in patients with atrial fibrillation, offering an alternative to traditional anticoagulants with a potentially improved safety profile. Its application is also being explored in other cardiovascular conditions where anticoagulation is critical.